ABAT — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Protocatechualdehyde (SCHEMBL36350)	0.57	3/20
SCHEMBL142988	0.57	3/20
SCHEMBL79952	0.52	3/20
SCHEMBL111227	0.52	3/20
SCHEMBL115626	0.52	3/20
SCHEMBL151496	0.52	3/20
SCHEMBL190410	0.52	3/20
SCHEMBL219109	0.52	3/20
SCHEMBL856316	0.47	3/20
SCHEMBL430962	0.47	3/20
SCHEMBL545072	0.47	3/20
SCHEMBL476028	0.42	3/20
SCHEMBL881431	0.40	3/20
SCHEMBL283036	0.38	3/20
SCHEMBL361345	0.62	2/20
SCHEMBL856737	0.61	2/20
SCHEMBL359491	0.59	2/20
SCHEMBL658295	0.58	2/20
SCHEMBL37131	0.52	2/20
4-Vinylphenol (SCHEMBL170622)	0.52	2/20

Clinical trials — most relevant to ABAT by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Clinical Evaluation of the Effect of Metformin in Sepsis	PHASE3	UNKNOWN
A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) Deficiency (Treatment naïve)	PHASE3	WITHDRAWN
Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With a Novel Form of Anaplerosis	PHASE2	COMPLETED
A Study of Bezafibrate in Mitochondrial Myopathy	PHASE2	COMPLETED
The Effects of Coenzyme A Combined With Abiraterone on Patients With CRPC	PHASE1/PHASE2	UNKNOWN
Acetylcarnitine and Insulin Sensitivity	PHASE2	COMPLETED
EPI-743 for Metabolism or Mitochondrial Disorders	PHASE1/PHASE2	COMPLETED
Atorvastatin, L-Carnitine and Non-Alcoholic Steatohepatitis	PHASE2	UNKNOWN
Trial on Treatment of Patients With Primary Hyperoxaluria Type I With Pyridoxal-phosphate	PHASE2	COMPLETED
Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) and Parkinson's Disease (PD) Patients	PHASE2	COMPLETED
Efficacy and Safety of the Treatment of Pyruvate Dehydrogenase Deficiency Patients With Glycerol Phenylbutyrate (RAVICTI)	PHASE2	RECRUITING
Metabolic Cofactor Supplementation in Obese Patients With Non-Alcoholic Fatty Liver Disease	PHASE2	COMPLETED
Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide Riboside	nan	UNKNOWN
Nutritional Therapy of the Deficits of Oxidation Mitochondrial of the Fatty Acids	nan	COMPLETED
Nephroprotective Effects of Carnitine and (PDE5) Inhibitor Agent Against Contrast Media-induced Nephropathy (CMN)	nan	UNKNOWN
A RETROspective Study of Patients With TK2d	nan	COMPLETED
Alternative Substrates in the Critically Ill Subject	nan	COMPLETED
The Effect of White Tea Consumption on Obesity	nan	COMPLETED
Effects of Parenteral L-carnitine Supplementation in Premature Neonates	nan	COMPLETED
Mitochondrial Assessment in Critical Ill Patients in Intensive Care	nan	NOT_YET_RECRUITING
A Prospective Study of the Disease Characteristics of Adult Patients With Long Chain Fatty Acid Oxidation Disorders	nan	COMPLETED
Impact of Metabolite Supplementation to Restore Mitochondrial Dysfunction During Septic Shock: a Preclinical Study	nan	RECRUITING
Tissue Sample Study for Mitochondrial Disorders	nan	ENROLLING_BY_INVITATION
Effect of Branched Chain Amino Acids on Muscle	nan	COMPLETED
ALDH2 Single Nucleotide Polymorphisms and Prognosis of Esophageal Cancer Patients	nan	RECRUITING
Effect of Sulfur Amino Acid Depletion and Acetaminophen on Plasma Glutatione	nan	COMPLETED
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia	nan	RECRUITING
Effect of Intradialytic Exercise In The United Arab Emirates	nan	COMPLETED
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes	nan	COMPLETED
Role of Amino Acids and Genetic Disorder in Pathogenesis of Heart Failure	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a ABAT binder may also engage these)

Protein	Name	Similarity
P61922	—	1.000	P61922 →
P80147	—	0.998	P80147 →
P50554	—	0.997	P50554 →
Q9BGI0	—	0.997	Q9BGI0 →
Q9ZPS3	—	0.955	Q9ZPS3 →
Q42521	—	0.954	Q42521 →
Q07346	—	0.953	Q07346 →
Q4R4U1	—	0.953	Q4R4U1 →
Q5U4X8	—	0.950	Q5U4X8 →
P82197	—	0.949	P82197 →
Q0II59	—	0.949	Q0II59 →
Q3ZC33	—	0.948	Q3ZC33 →
Q6GV29	—	0.947	Q6GV29 →
Q64380	—	0.947	Q64380 →
Q5R5F8	—	0.945	Q5R5F8 →
Q9NVE7	—	0.945	Q9NVE7 →
Q41141	—	0.945	Q41141 →
Q9LSH2	—	0.945	Q9LSH2 →
P52848	—	0.945	P52848 →
Q923S8	—	0.945	Q923S8 →
Q8HXW0	—	0.944	Q8HXW0 →
B1WC68	—	0.943	B1WC68 →
Q9QZ08	—	0.943	Q9QZ08 →
Q02353	—	0.942	Q02353 →
Q4ZHR9	—	0.941	Q4ZHR9 →
Q9Z244	—	0.941	Q9Z244 →
O46560	—	0.941	O46560 →
B1H369	—	0.941	B1H369 →
Q2KIG0	—	0.940	Q2KIG0 →
P38024	—	0.940	P38024 →